Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension
Itching is a prevalent plaque psoriasis symptom. Ixekizumab, an IL-17A antagonist, has demonstrated rapid, significant improvements in itch severity over 12 weeks in Phase III psoriasis trials (UNCOVER-1, UNCOVER-2). We assessed the long-term (through 60 weeks) effect of ixekizumab maintenance thera...
Bewaard in:
Hoofdauteurs: | , , , , , , , |
---|---|
Formaat: | Boek |
Gepubliceerd in: |
Medical Journals Sweden,
2017-10-01T00:00:00Z.
|
Onderwerpen: | |
Online toegang: | Connect to this object online. |
Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|
Internet
Connect to this object online.3rd Floor Main Library
Plaatsingsnummer: |
A1234.567 |
---|---|
Kopie 1 | Beschikbaar |